Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2019 Jul 9.

Published in final edited form as: Lancet Diabetes Endocrinol. 2018 Feb 27;6(5):392–403. doi: 10.1016/S2213-8587(18)30027-5

Figure 1. — Distributions of control of CVD risk factors: (A) hypertension, (B) dyslipidemia, and (C) smoking status by glycemic status, 1988–2014. T1, 1988–1994; T2, 1999–2004; T3, 2005–2010; T4, 2011–2014. Hypertension was classified as: not treated (no antihypertensive medication use and BP ≥140/90 mm Hg); treated, not controlled (antihypertensive medication use and blood pressure ≥140/90 mm Hg); treated, controlled (antihypertensive medication use and blood pressure <140/90 mm Hg). Dyslipidemia was classified as: not treated (no lipidlowering medication use and non-HDL cholesterol ≥160 mg/dL); treated, not controlled (lipid-lowering medication use and non-HDL ≥160 mg/dL); treated, controlled (lipid-lowering medication use and non-HDL <160 mg/dL). Smoking status by self-report was classified as current smoker, former smoker, and never smoker.

Figure 1. — Distributions of control of CVD risk factors: (A) hypertension, (B) dyslipidemia, and (C) smoking status by glycemic status, 1988–2014. T1, 1988–1994; T2, 1999–2004; T3, 2005–2010; T4, 2011–2014. Hypertension was classified as: not treated (no antihypertensive medication use and BP ≥140/90 mm Hg); treated, not controlled (antihypertensive medication use and blood pressure ≥140/90 mm Hg); treated, controlled (antihypertensive medication use and blood pressure <140/90 mm Hg). Dyslipidemia was classified as: not treated (no lipidlowering medication use and non-HDL cholesterol ≥160 mg/dL); treated, not controlled (lipid-lowering medication use and non-HDL ≥160 mg/dL); treated, controlled (lipid-lowering medication use and non-HDL <160 mg/dL). Smoking status by self-report was classified as current smoker, former smoker, and never smoker.